Tag: Patent

Currently, the migraine-preventative medication Qulipta, also known by its active ingredient atogepant, does not have a generic version available on the market. This means patients must rely solely on the brand-name product, which often comes with a higher price tag. Understanding the factors that determine generic availability can help patients and healthcare providers navigate the landscape of migraine treatment options and manage costs.

As of 2025, there is no FDA-approved generic version of semaglutide available in the United States, with pharmaceutical patents protecting brand-name drugs like Ozempic, Wegovy, and Rybelsus for years to come. This has led to widespread consumer interest in more affordable alternatives, including exploring if you can buy generic semaglutide or other unapproved options, which carry significant risks.

Veozah, the brand-name medication with the active ingredient fezolinetant, was approved by the FDA in May 2023 for treating moderate to severe hot flashes due to menopause. As of late 2025, there is **no generic for Veozah** available on the market.